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a b s t r a c t
Adeno-associated virus serotype 8 (AAV8) is a promising vector for liver-directed gene therapy. Although
efﬁcient uncoating of viral capsids has been implicated in AAV8's robust liver transduction, much about
the biology of AAV8 hepatotropism remains unclear. Our study investigated the structural basis of AAV8
liver transduction efﬁciency by constructing chimeric vector capsids containing sequences derived from
AAV8 and AAV2 – a highly homologous yet poorly hepatotropic serotype. Engineered vectors containing
capsid variable regions (VR) VII & IX from AAV8 in an AAV2 backbone mediated near AAV8-like
transduction in mouse liver, with higher numbers of chimeric genomes detected in whole liver cells and
isolated nuclei. Interestingly, chimeric capsids within liver nuclei also uncoated similarly to AAV8 by
6 weeks after administration, in contrast with AAV2, of which a signiﬁcantly smaller proportion were
uncoated. This study links speciﬁc AAV capsid regions to the transduction ability of a clinically relevant
AAV serotype.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Vectors based on the non-pathogenic parvovirus adeno-
associated virus (AAV) are currently among the most promising
gene delivery systems for use in human gene therapy, owing to an
ability to mediate safe and stable transgene expression in many
non-dividing mammalian cell types (Kotin, 1994). AAV vectors
consist of a single-stranded DNA genome packaged in a non-
enveloped capsid of icosahedral symmetry (Xie et al., 2002). The
capsid protein includes a group of conserved strands and several
highly diversiﬁed interstrand loop regions termed “variable
regions” that deﬁne the various AAV serotypes (Govindasamy
et al., 2006).
One of the ﬁrst AAVs to be discovered and the most promi-
nently investigated serotype has been AAV2, both in studies aimed
at elucidating the cell biology of AAV and in studies investigating
AAV's potential as a therapeutic vector (Bartlett et al., 1998).
However, in the past decade, a large number of other AAV sero-
types with varying properties and tropisms have been identiﬁed
(Wu et al., 2006; Gao et al., 2002; Lochrie et al., 2005).
A notable example is AAV serotype 8, which has emerged as a
clinically relevant alternative to AAV2 owing to its remarkable
ability to mediate robust transgene expression in tissues not
efﬁciently transducible by AAV2, such as liver (Wang et al., 2005;
Hurlbut et al., 2010), retina (Vandenberghe et al., 2008, 2011) and
skeletal muscle (Louboutin et al., 2005). AAV8 consistently
achieves 10–100-fold improvement in gene transfer efﬁciency
over AAV2 in hepatocytes (Gao et al., 2002), with minimal lag
between vector administration and onset of expression (Nakai
et al., 2002).
The biological basis for high liver transduction with AAV8 is not
fully understood, although an ability to efﬁciently uncoat vector
particles is currently suggested as a potential feature accounting
for this supremacy (Thomas et al., 2004). More recently, the
kinetics of AAV uncoating have also been proposed as a rate-
limiting step in the transduction mediated by self-complementary
AAV6 in cardiac cells (Sipo et al., 2007), and uncoating efﬁciency
has been linked to stability of transient dsDNA AAV2 and AAV8
genomes (Wang et al., 2007). It remains unclear how structural
differences between AAV serotypes might be affecting their
characteristic uncoating rates. This is especially perplexing for
the case of AAV2 and AAV8, given that the AAV8 capsid is 82%
homologous in primary sequence and displays high conservation
in tertiary structure to AAV2 (Nam et al., 2007), which is a poor
liver transducer.
Chimeric vectors constructed by swapping of variable capsid
protein domains between AAV serotypes have been employed to
identify structural determinants of characteristic serotype trop-
isms, and this approach has been successful in mapping AAV1's
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muscle tropism, for example (Hauck and Xiao, 2003). Domain
swap experiments have indicated that many residues located
within the longest interstrand loop – the GH loop, which contains
ﬁve of the nine variable regions – to be the key determinants of
serotype- and context-speciﬁc transduction ability (Van Vliet et al.,
2008; DiMattia et al., 2012). Similar strategies aimed at uncovering
capsid regions responsible for the hepatotropism of AAV8 have
likewise implicated variable portions located at the three-fold
symmetry axis. A recent report also identiﬁed regions on the AAV9
capsid that may aid in delaying blood clearance (Kotchey et al.,
2011). To date, no domain-swapping studies have evaluated
parameters other than transduction, such as intracellular genome
copy number or uncoating state (Shen et al., 2007; Raupp et al.,
2012; Gurda et al., 2012).
In the current study, we identify two variable regions facing the
two-fold symmetry axis as possible capsid structural determinants
of AAV8's remarkable liver transduction and, for the ﬁrst time,
correlate speciﬁc AAV8 capsid portions with cell entry, nuclear
entry and vector uncoating ability. We show that an AAV2-based
chimeric vector containing these variable regions from AAV8
achieves signiﬁcantly improved cellular and nuclear entry over
AAV2, and is able to fully uncoat by 6 weeks after injection, unlike
its parent vector. This chimeric vector retained heparin-binding
ability akin to AAV2, supporting the notion that transduction
differences are effected at post-attachment steps. Additionally,
the chimera displayed an altered antigenic proﬁle in vitro com-
pared to its parental serotypes, indicating that its capsid surface
could harbor changes extending beyond the exact mutated regions.
Results
Rational design, generation and in vitro testing of chimeric AAV2
vectors containing putative capsid transduction domains from AAV8
Previous work had suggested that the capsid portion mediating
high liver transduction by AAV8 was located in variable portions
surrounding the three-fold axis of symmetry, in large VP3 areas
encompassing VR IV, V, and VII as well as a few other disparate
amino acids (Shen et al., 2007; Raupp et al., 2012). In an effort to
further pinpoint the key capsid residues effecting AAV8 transduc-
tion, we began by generating chimeric vectors containing nar-
rower swaps that replaced only the most surface-exposed loops of
VR IV, V and VIII on an AAV2 backbone. Mice were injected
intravenously with chimeric vectors expressing ﬁreﬂy luciferase
from the CB7 promoter. None of the chimeras amenable to scaled
production and puriﬁcation for in vivo testing yielded liver
transduction greater than that achieved by AAV2 (Fig. S1a), which
corroborated most of the published results mentioned above for
those particular residues. Expressionwas generally low with AAV2,
AAV8 and all the chimeras in spleen and lung (Fig. S1c and d).
AAV8-mediated expression in heart was one log higher than AAV2,
with four out of the six chimeras tested showing expression
similar to that observed with AAV8 (Fig. S1b). The divergence in
performance of the chimeras between heart and liver is interesting
and underscores the documented involvement of three-fold pro-
trusions in vector–cell interactions; however, the poor perfor-
mance of all chimeras in liver led us to search for a domain of
interest residing outside the three-fold axis.
We next focused on the two-fold symmetry axis, generating
seven more AAV2-based chimeras containing variable regions VR I,
VII and IX – which face the two-fold axis – from AAV8, either alone
or in every possible combination. Fig. 1a indicates the locations of
these regions in a structural amino acid alignment of AAV2 and
AAV8. In vitro experiments assessing chimeric vector assembly as
well as transduction ability in HEK293 cells showed that all these
AAV2 chimeric vectors containing small regions from AAV8 were
able to assemble into functional particles and mediated high,
AAV2-like transduction ability in vitro (Fig. S2).
An AAV2 chimera containing VR VII & IX from AAV8 transduces
mouse liver nearly as well as AAV8
After testing the performance of these seven chimeras in vitro,
chimeric vectors were produced in larger scale and puriﬁed
through iodixinal or cesium chloride gradients for in vivo testing.
Two of the vectors – the chimera containing all three regions
swapped and the one containing regions I & VII – did not with-
stand the production process, and were therefore not tested in
mice. For the remaining chimeras, in vivo transduction was
assessed for the liver, heart, spleen and lung of 6–8 week-old
male C57BL/6 mice following intravenous injection of 1011 GC of
vectors encoding ﬁreﬂy luciferase under the CB7 promoter. All
chimeras containing AAV8 regions VII and/or IX gave rise to
vectors with 100-fold increased expression over AAV2 in liver
as well as in heart lysates, where the expression mediated by AAV8
is typically high. In lung and spleen, where expression is typically
low both with AAV8 and AAV2, modest (o10-fold) increases in
expression were observed with some chimeras, although results
for these organs were more highly variable across animals and
therefore not indicative of a marked change in tropism (Fig. 2).
The best-performing chimera in liver was the VR VII & IX
chimera, and we proceeded to further characterize this vector in
an effort to obtain insight into biological mechanisms accounting
for AAV8 liver transduction ability. Analysis of this chimera's
expression over a time course revealed that this vector also
exhibited fast expression kinetics, achieving its maximal luciferase
activity by day 4, similarly to AAV8 (Fig. 3a). Fig. 1b shows the
location of regions VII and IX in a structural representation of the
assembled capsid. This chimera is entirely identical to AAV2 except
for 17 amino acids in VP3. Additionally, further evaluation of
chimera expression following intramuscular injection (Fig. S3)
and subretinal injection (Fig. S4) showed that the chimera did
not mediate high, AAV8-like transgene expression levels in muscle
or eye, indicating that effects of the AAV8 variable regions VII & IX
on the chimera to be chieﬂy liver- and heart-speciﬁc in terms of
in vivo transduction.
Chimeric vector genomes exhibit increased cell entry, nuclear entry
and persistence over AAV2 in mouse liver
In an attempt to determine at which step in the vector trans-
duction cycle the chimeric vector might be distinct from AAV2 in
the liver, we ﬁrst quantiﬁed vector genome copy number in DNA
extracted from liver cell homogenates using a Taqman qPCR assay
recognizing the vector's polyadenylation sequence (Fig. 3b). Typi-
cally, we detect substantially higher amounts of AAV8 genomes in
liver compared to AAV2 when dosed with equivalent amounts of
vector (Gao et al., 2002) [Wang and Wilson, unpublished results],
an observation that was once again replicated in this experiment.
Genome copy assessment in nuclei isolated from freshly dissected
livers revealed that AAV8 also greatly surpassed AAV2 in nuclear
entry (Fig. 3c). As for mice injected with chimera, both the total
liver and the nuclear genome copy numbers were substantially
greater than those reached following AAV2 injection, although still
lower than what was observed with AAV8 (Fig. 3b and c).
Nearly all chimeric capsids that localize to liver nuclei eventually
undergo uncoating
The results described above show that this chimeric vector
appears to have a heightened ability to enter the liver compared
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to AAV2. Additionally, at earlier time points (days 1 and 4), the
chimera's ability to translocate into cell nuclei was also much
above that of AAV2, and, even at later time points, the absolute
quantity of nuclear-localized chimera remained 5–10-fold above
that of AAV2. In order to verify whether the increased presence of
vector genome entities in cells and nuclei seen with the chimera
also corresponded to an increase in uncoated genomes, we
decided to quantify how many of the nuclear chimeric capsids
underwent uncoating over time. A limited ability to uncoat has
previously been proposed as the reason for AAV2's modest liver
transduction as presented by Thomas et al. (2004). In order to
accomplish this, we digested free vector genomes in isolated liver
nuclei with DNaseI prior to DNA extraction. Intriguingly, at early
time points, the relative number of uncoated chimera genomes
most resembled AAV2 (less than 50% uncoated, Fig. 3d), although
the effective number of released genomes was higher for the
chimera, likely owing to the higher nuclear entrance seen for the
chimera (Table 1). However, by 21 days after injection, the majo-
rity of chimera particles had disassembled (70% at day 21; 92% at
day 42), akin to what we observed for AAV8 in agreement with
Thomas et al. (88% at day 21, 90% at day 42; Fig. 3d). Interestingly,
for time points when expression had reached its respective steady-
state level, the absolute number of uncoated genomes in the
Thomas et al. report was roughly comparable to those obtained
Fig. 1. Generation of AAV2-based chimeric vectors containing AAV8 variable regions facing the two-fold symmetry axis. (a) Structure-based amino acid alignment of AAV2
and AAV8 capsid sequences. Chimeric vectors were generated by swapping AAV8 variable regions (VR) I, VII and IX into the AAV2 backbone. Dots represent identical amino
acids. The variable surface loop regions are numbered I–IX. Regions I, VII and IX are highlighted. Sequences were aligned using BioEdit, version 7.0.5.3 (Ibis Biosciences,
Carlsbad, CA, USA). (b) Visualization of VR VII (in cyan) & IX (in chocolate), which resulted in a high-transducing vector, at the two-fold axis of the assembled chimeric capsid.
All residues from regions VII & IX are highlighted. Image was generated using PyMOL Molecular Graphics System.
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Fig. 2. In vivo expression of all originally produced chimeras in mouse liver, heart, lung and spleen lysates at day 21 after intravenous injection. About 11011 genome copies
of vectors encoding a Fireﬂy Luciferase transgene under the CB7 promoter (CB7.ffLuc.RBG) were injected intravenously into young C57BL/6 mice. Three weeks later, luciferase
activity in Relative Light Units was measured in lysates obtained from liver (a), heart (b), spleen (c) and lung (d) using a Luciferase Assay System. Data were normalized to
protein concentration. The dash denotes the median value among replicates.
Fig. 3. Characterization of mouse liver transgene expression mediated by AAV8, AAV2 and a chimeric vector containing variable regions VII and IX from AAV8 in an
otherwise fully AAV2 backbone (henceforth referred to as ‘chimera’). (a) Luciferase activity in liver lysates was measured at ﬁve time points after intravenous injection of 1011
genome copies of AAV2, AAV8, or AAV2-8 VR VII & IX.CB7.fﬂuc.RBG into 6–8 week old C57BL/6 mice. (b) Total genome copy number was determined in DNA isolated from
liver pieces by qPCR using a probe recognizing a portion of the vectors’ RBG polyA sequences. (c) Nuclear genome copy number was determined in DNA extracted from
highly pure isolated liver nuclei using the same qPCR assay as (b). (d) The percentage of uncoated vector genomes was obtained by subtracting the number of genome copies
detected in DNA isolated from nuclei pretreated with 50 U DNAseI from the total measured number of nuclear vector genomes. Data are presented as mean7SEM (n¼7
mice/group across three separate experiments utilizing different vector production lots).
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here for both AAV2 and AAV8, despite discrepancies in the proportion
of cell and, to a lesser extent, nuclear entry observed for each serotype
at some time points.
The chimera's high expression in liver is not due to altered cell
surface-binding
Although residues within the chimeric regions have not been
directly implicated in the heparin binding of AAV2, a recent
structural study revealed the binding site for the heparan sulfate
proteoglycan receptor to be more extensive than previously appre-
ciated (O’Donnell et al., 2009). We therefore veriﬁed whether
AAV2's heparin binding was retained in the chimera, given that
disruption of heparan sulfate proteoglycan receptor attachment has
been shown to signiﬁcantly alter AAV2 liver tropism (Asokan et al.,
2009) and that AAV chimeric capsids could potentially harbor
topological capsid changes extending beyond the exact position of
the swapped regions. Using a heparin column, we conﬁrmed that
the chimera does in fact retain binding to AAV2's primary attach-
ment receptor (Fig. 4), providing evidence that the chimera's
increased transduction is mediated by mechanisms other than the
loss of heparin binding.
In vitro characterization reveals the chimera has an antigenic proﬁle
distinct from AAV2
Since previously reported AAV2-based chimeric vectors exhi-
biting altered transduction proﬁles were also found to be anti-
genically unique (Asokan et al., 2009; Bowles et al., 2012), we
decided to evaluate the chimera for binding to AAV2 antibodies.
We ﬁrst tested whether the chimera was able to bind the mono-
clonal antibody A20, which recognizes a conformational epitope
comprising residues across three symmetry-related monomers in
intact AAV2 capsids (Govindasamy et al., 2006; Lochrie et al.,
2005; Wobus et al., 2000; McCraw et al., 2012). Abrogation of
A20 binding sites has been suggested to correspond with serum
neutralization, since capsid mutations inhibiting A20 binding
have been shown to confer resistance against neutralization by
polyclonal antiserum (Lochrie et al., 2005). Although the three
originally mapped epitopes for A20 on AAV2 are preserved in the
chimera, residues within or around the chimeric regions have
been implicated in A20 binding in mutagenesis studies (Lochrie
et al., 2005), and, most recently, three of the residues mutated in
the chimera were among several others identiﬁed as possible
points of contact between A20 and the AAV2 capsid surface in a
cryo-electron microscopy structure of AAV2 complexed with A20
(McCraw et al., 2012). In agreement with the more recent results,
we detected no binding when chimera was blotted with A20
(Fig. 5a), although a faint residual signal was visible after overnight
ﬁlm exposure (Fig. S5).
Finally, we subjected the chimera to an in vitro neutralizing
antibody assay in which Huh7 cells were transduced at an MOI of
104 in the presence of AAV antisera. Fig. 5b shows that not only
was the chimera less neutralizable by AAV2 antiserum, it was also
rendered modestly neutralizable by AAV8 antiserum. This result
was further corroborated by immunoblotting with AAV2 and AAV8
antisera, both of which were able to bind to the chimera (Fig. 5c).
Discussion
In this study we sought to identify and characterize possible
capsid structural determinants of AAV8's remarkable liver trans-
duction ability by constructing AAV2-based chimeric capsids
containing small variable regions from AAV8 and characterizing
their presence in target cells over time. We found that a vector
containing VR VII & IX from AAV8 consistently mediated in vivo
transgene expression levels well above AAV2, closely matching
AAV8 at later time points in most instances. Chimeric genomes
were typically detected in liver cells as well as in nuclei in greater
amounts than AAV2. Further characterization revealed that, unlike
AAV2, most nuclear-present chimeric particles were able to undergo
uncoating by 6 weeks after injection, raising the possibility that
uncoating impinges at least partially on capsid performance.
However, before considering potential mechanistic explanations
about the behavior seen with the chimera, an analysis of what
can be inferred about its parental serotypes (AAV2 and AAV8) alone
is warranted.
In the report by Thomas et al. (2004), uncoating ability
emerged as a key step accounting for the high transduction seen
with AAV8 in liver, since by 6 weeks after vector injection – when
the expression mediated by AAV8 was 12-fold higher than AAV2 –
the number of uncoated genomes was the parameter with the
largest difference between AAV8 and AAV2. For the same time
point in the current report – when AAV8 expression was similarly
13-fold higher than AAV2 – uncoated genome present in nuclei
was also the parameter that diverged the most between serotypes
(Table S1), corroborating Thomas et al. As for the marked quanti-
tative differences in cellular and nuclear genome copy number
between our reports, we noted that they occurred largely at early
time points, when expression is still rising and has not yet reached
steady-state. For instance, 1 day after vector injection, we found
that the number of AAV8 particles present in liver cells was
roughly 4-fold higher than AAV2 (Fig. 3b). In contrast, also 1 day
after injection, AAV8 entered liver cells roughly 9-fold less than
AAV2 in the report by Thomas et al. Nonetheless, in both reports,
more than half of the AAV8 cellular particles had trafﬁcked into
the nucleus on day 1 (51% this report; 60% Thomas et al.), whereas
AAV2 nuclear entry was seen for only 6% (this report) or 9%
(Thomas et al.) of cellular vector particles. Fittingly, the absolute
difference in the number of nuclear genomes between our reports
for AAV8 at day 1 (23 in our report, 3 in Thomas et al.)
Table 1
Average number of uncoated vector genomes on nucleus (refer to Fig. 3d).
Time (days) AAV2 AAV8 AAV2-8VR VII, IX
1 0.170.10 9.870.70 1.670.14
4 0.670.11 12.271.41 3.770.35
7 1.170.17 22.273.18 7.771.41
21 0.770.33 15.471.06 3.870.81
42 0.270.02 8.972.75 3.670.23
While Fig. 3d shows the percentage of uncoated genomes relative to the total
genome copy number in nucleus, this table shows the absolute number of uncoated
entities in the nuclei of liver cells transduced with each vector (mean7SEM).
Fig. 4. AAV2-8 VR VII, IX retains heparin afﬁnity. About 51010 GC of each vector
were loaded onto a heparin column using a FPLC system. Columns were washed
with 10 volumes of PBS and eluted with 5 volumes of PBS containing 1 M NaCl.
Collected fractions were heated at 95 1C for 5 min then applied onto a PVDF
membrane and subsequently blotted with B1 antibody.
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correlates with the 1000-fold higher AAV8-mediated expression
seen here at day 1, compared to the 100-fold difference between
the two serotypes in Thomas et al. at the same time point.
Thus, despite such quantitative differences, nuclear-localized as
well as uncoated AAV2 and AAV8 genome numbers were roughly
compatible across our data sets, particularly for time points when
each serotype's expression was at its respective maximal level.
Further comparison of our data with the data presented by
Thomas et al. also revealed a remarkably similar increase in
uncoating efﬁciency of AAV8 over AAV2 (AAV8 exhibited 1.6-fold
higher uncoating efﬁciency here; 1.5-fold in Thomas et al.; Table S1).
Finally, across all our iterations of experiments comparing AAV2,
AAV8 and the chimera in mice (utilizing different vector lots harbo-
ring different transgenes, promoters and polyadenylation sequences),
the effective number of uncoated genomes emerged as the overall
least variable parameter (data not shown). We also noted that the
contribution of each free AAV8 nuclear genome to its steady-state
transduction level was not dissimilar from the contribution of each
free AAV2 nuclear genome to its own maximal transduction level.
Thus, it is admissible to conclude that a tendency of a vector to
uncoat efﬁciently will ultimately result in higher transduction levels.
This underscores uncoating as a contributor in AAV8 liver transduc-
tion, as originally proposed by Thomas et al. To date, a handful of
other reports have also indicated uncoating rates to be one compo-
nent of the expression ability of AAV2, AAV6 and AAV8 in various
target cells (Zhong et al., 2004; Wang et al., 2007; Sipo et al., 2007).
Now considering the AAV2 chimera harboring variable regions
VII and IX from AAV8, we observed that this vector surprisingly
resembled AAV8 not only in uncoating ability, but in all evaluated
parameters, exhibiting markedly efﬁcient cellular entry, nuclear
trafﬁcking, capsid uncoating, transduction kinetics and expression
level compared to AAV2. At 6 weeks after injection – when
chimera-mediated expression was 11-fold above AAV2 – the
discrepancy between chimera and AAV2 uncoated genomes was
the highest, and the proportion of uncoated genomes out of total
nuclear genomes was 1.7-fold above AAV2, which is comparable to
the 1.6-fold increase in uncoating efﬁciency as we saw for AAV8.
Since our results do not directly address possible biological
reasons for how replacing these 17 AAV8-speciﬁc residues into
AAV2 could be acting to increase cellular entry, nuclear transloca-
tion or uncoating, we are unable to delineate whether any one
transduction step was chieﬂy responsible for effecting vector
transduction level as mediated by the chimera. An increased
ability to enter cells readily did not correspond to increased
AAV2 nuclear localization for Thomas et al., while relative nuclear
localization was efﬁcient for all serotypes in both reports at later
time points. Nonetheless, it remains interesting that the chimeric
vector did acquire AAV8-like uncoating behavior.
In trying to consider possible mechanisms behind the chimera's
intriguing gain in uncoating efﬁciency despite its near-identical AAV2
secondary sequence, it can either be predicated that speciﬁc residues
in VR VII & IX play a direct role in uncoating, or that swapping
those regions results in broader changes at the capsid surface that
ultimately facilitate uncoating. Our results indeed suggested the
capsid surface of the chimera might differ from AAV2 beyond
variable regions VII and IX themselves, based on the altered AAV2
and AAV8 antisera neutralization proﬁles shown in Fig. 5. The
location of the chimeric VR – facing the two-fold symmetry axes
all around the capsid – also allows for an intriguing mechanistic
hypothesis to account for the chimera's uncoating ability.
Fig. 5. Altered neutralization proﬁle of AAV2-8 VR VII & IX. (a) The monoclonal antibody A20, which binds speciﬁcally to intact AAV2 capsids, did not bind to dot-blotted
chimeric vector, which was somewhat expected given recent evidence that residues changed in the chimera might be contacted upon A20 surface binding. As a control, all
vectors were heated at 95 1C for 5 min and detected with B1 antibody, which binds to non-intact capsids of various serotypes. (b) The chimera is more neutralizable by AAV8
antiserum compared to AAV2. Huh7 cells were transduced with CB7.fﬂuc.RBG vectors at an MOI of 104 in the presence of various concentrations of AAV2 antiserum, AAV8
antiserum or IVIG control serum. About 48 h later, luciferase activity was quantiﬁed. Data represent the highest serum dilution factor at which transduction levels were
below 50% of control samples containing no antiserum. (c) AAV8 antiserum is shown to be able to bind to chimera, corroborating the result shown in (b). Load control lanes
were probed in a separate blot with a serum that cross-reacts with all serotypes (VP51).
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In a recent report by Nam et al. (2011), AAV8 crystal structures
were obtained at physiological pH as well as in lower pH levels
akin to those encountered in the late endosomal lumen. In
structures obtained at pH 4.0, Nam et al. observed signiﬁcant
side-chain conformational rearrangements in speciﬁc residues
termed the “pH quartet,” which resulted in a detectable weaken-
ing of the two-fold capsid interface. While the pH quartet residues
themselves are widely conserved across various AAV serotypes,
Nam et al. noted that some of the pH-induced changes seen for
AAV8 might not occur in all serotypes depending on their exact
positioning within each capsid. For example, at physiological pH,
AAV8 residue E566 formed hydrogen interactions with R392 (on a
three-fold related monomer) as well as with Y707 (on a two-fold
related monomer). At lower pH, not only were those interactions
lost, but Y707 also oriented toward the two-fold axis and E566 was
instead predicted to bond with residue H529, which could actively
destabilize some interactions between monomers or act to induce
otherwise destabilizing conformational changes. In AAV2, how-
ever, bond distance calculations based on the available crystal
structure (obtained at physiological pH) suggest that the AAV2
residues corresponding to E566, R392 and Y707 appear too far to
interact with one another, suggesting that capsid interactions
stabilizing AAV2 fall outside this region of the capsid. Therefore,
if such pH-induced capsid changes are in fact contributing to AAV8
capsid destabilization and facilitating subsequent uncoating, it
would follow that the inability of AAV2 capsids to undergo pH-
dependent changes might partially account for AAV2's documen-
ted uncoating inefﬁciency.
Interestingly, we noted that the locations of VR VII & IX in the
chimeric vector described in this report are each immediately
adjacent to one of the pH quartet residues (E563 and Y704 in
AAV2/chimera numbering, respectively; Fig. 6). Thus, it is tempting
to postulate that the surface differences between AAV2 and the
chimeric capsid might allow some of the pH-inducible changes
seen for AAV8 to be recapitulated in the chimera; in this case,
reconstituting pH quartet structure in AAV2 would actively desta-
bilize the capsid in low pH. This hypothesis offers a possible
mechanism to account for the uncoating of most nuclear-localized
chimera particles we observed, although we are unable to draw
more concrete conclusions.
Prior to generating the chimera containing variable regions
facing the two-fold axis, our ﬁrst attempt at identifying capsid
regions mediating liver transduction was designed as an effort
to follow up on previous work by Shen et al. (2007), which had
suggested loop regions surrounding the three-fold symmetry axes
as putative liver transduction domains. Shen et al. had indicated
that swapping residues corresponding to VR IV in the terminology
used in this paper from AAV8 into AAV2 resulted in a vector that
transduced liver about 10-fold better than AAV2 at early time
points and modestly above AAV2 later on. The reciprocal hybrid
vector containing VR IV from AAV2 in an AAV8 backbone also
resulted in a marked reduction in AAV8 transduction. Similarly, bi-
directional swaps corresponding to VR VIII plus three additional
discrepant residues each resulted in markedly low-expressing
vectors, leading to the hypothesis that those regions were exerting
critical roles in vector transduction. In hopes of conﬁrming the
results reported by Shen et al. and further pinpointing putative key
capsid regions, we generated narrower swaps of AAV8 VR IV and
VIII into AAV2. Additionally, since non-contiguous residues within
the primary amino acid sequence often come into spatial proxi-
mity upon assembly, we also constructed chimeras containing
narrower swaps of VR IV, V and VIII all together, aiming to
preserve potentially critical surface interactions between VRs in
different monomers. However, none of these vectors showed any
increase in expression over AAV2 in liver, heart, lung or spleen.
More recently, Asokan et al. (2009) also reported a similar liver
detargeting in an AAV2 hybrid vector where the heparin-binding
portion of VR VIII (which corresponded to our narrowest VR VIII
swap) was replaced with the corresponding residues from AAV8.
In contrast, another recent report by Raupp et al. (2012) found that
hybrid AAV2 vectors containing portions from AAV8 VR VIII
exhibited increased liver as well as heart expression, with the
same effect seen for the reciprocal version of this hybrid. Perhaps
one caveat for experiments employing modiﬁed AAV capsids is
that disruption of expression compared to original serotypes is not
necessarily as informative as a gain in expression or a change in
tropism.
Swapping domains onto different serotype backbones does not
predictably transfer speciﬁc tropisms onto the newly generated
hybrids – even when the domains exert known speciﬁc roles, such
as receptor binding. A notable example of this is an attempt to
confer heparin-binding ability to AAV5 by transferring AAV2's
heparin-binding domain onto the AAV5 capsid, which resulted in
a non-infectious vector (Opie et al., 2003). On the other hand,
residues mediating AAV1 muscle transduction (Hauck and Xiao,
2003) were able to confer muscle tropism when transferred to
AAV2 (Bowles et al., 2012). Interestingly, the heparin binding-
deﬁcient AAV2 hybrid vector generated by Asokan et al. also
displayed remarkable muscle expression, whereas the heparin-
binding ability of AAV1 reportedly had little effect on the high
muscle transduction mediated by this serotype (Hauck and Xiao,
2003). Of note, a reciprocal version of the chimeric vector in which
VR VII & IX from AAV2 were placed onto an AAV8 backbone did
show a reduction in expression, albeit a modest one, further
underscoring the complexity of capsid–cell interactions.
Thus, a precise molecular understanding of the capsid–cell
interactions that contribute to AAV liver transduction remains to
be delineated, although some clues are emerging. It will be
interesting to identify what host factors may be involved, or to
understand how this chimeric vector is able to enter cells and
nuclei better than AAV2. Other recent mechanistic insights into
Fig. 6. Positioning of AAV2-8 VR VII & IX chimeric regions in relation to “pH
quartet” residues. A pair of two-fold symmetry related AAV2 VP3 monomers are
shown in gray. The black oval indicates the two-fold symmetry interface. The cyan
noodle denotes VR VII; the chocolate noodle marks VR IX. The colored balls
represent key residues that engage in pH-sensitive hydrogen interactions. Red,
residue Y704; orange, residue E563; green, residue H526. Image was generated
using PyMOL Molecular Graphics System.
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AAV transduction have suggested that serotype-speciﬁc protease
sites may exist on the AAV capsid, some of which may also be pH-
dependent (Salganik et al., 2012). Cathepsins B and L, which have
been found to cleave AAV8 in vitro with higher efﬁciency than
AAV2 (Akache et al., 2007), may also be contributing to capsid
dissociation. Finally, there is the possibility that AAV particles that
enter the nucleus ﬁrst localize to nucleoli, necessitating an addi-
tional transport step prior to capsid uncoating in the nucleoplasm
(Johnson and Samulski, 2009).
Ultimately, we hope that studying this chimeric vector will aid
in the discovery of speciﬁc mechanisms or cellular host factors
involved in AAV8's remarkable and clinically relevant liver trans-
duction properties.
Materials and methods
Cloning of chimeric AAV capsid trans-packaging plasmids
Chimeric capsid sequences were cloned using splicing by overlap
extension (SOE) PCR (Horton et al., 1990). Chimeric cap genes were
subsequently cloned onto a packaging plasmid containing AAV2 rep
by digestion with restriction endonucleases HindIII and SpeI fol-
lowed by ligation with T4 ligase. Competent Stbl3 Escherichia coli
(Invitrogen, Grand Island, NY) were transformed with ligated
plasmids, and resulting single colonies were ampliﬁed by Megaprep
(QIAGEN, Germany). All chimeric cap gene sequences were con-
ﬁrmed by full-length DNA sequencing (QIAGEN) prior to vector
production for in vivo studies.
Production of AAV vectors for preliminary in vitro tests
Recombinant AAV vectors expressing ﬁreﬂy Luciferase (ffLuc)
under the cytomegalovirus (CMV) promoter and ﬂanked by AAV2
inverted terminal repeats were produced by triple calcium
phosphate transfection of human embryonic kidney 293 cells
(HEK293). Brieﬂy, 3.25 μg of a cis plasmid containing the trans-
genic cDNA, 3.25 μg of a trans-packaging plasmid construct con-
taining the AAV2 rep gene along with the AAV8, AAV2 or chimeric
cap gene and 6.5 μg of an Adenovirus helper plasmid (pAdΔF6)
were added to 6-well plates containing cultured cells at 90%
conﬂuence. Two days after transfection, cells were harvested by
scraping followed by repeated freeze/thaw cycles. Lysates were
cleared by centrifugation for 10 min at 4000 RPM (4 1C). Vector
genome copy number per milliliter (GC/mL) was determined by
real-time quantitative PCR using primers and a Taqman probe
speciﬁc for the vector's polyadenylation sequence.
In vitro transduction assays
Crude small-scale vector preparations of AAV vectors were
added to 1105 HEK293 cells seeded onto black-walled, clear-
bottomed 96-well plates at an MOI of 104. Two days after transduc-
tion, luciferase activity was measured using a luminometer after
injection of 100 mL 0.15 mg/mL Luciferin into each well.
Scaled production and puriﬁcation of vectors for animal experiments
AAV vector was made by a modiﬁed version of previously
described methods (Lock et al., 2010). Brieﬂy, a 10-layer cell stack
(1.5 L total culture volume) containing 75% conﬂuent HEK293 cell
monolayers was triple-transfected using PEI. Medium was treated
with turbonuclease and 0.65 M NaCl, cleared by centrifugation
and subsequently concentrated by tangential ﬂow ﬁltration. The
resulting lysate was then puriﬁed either over a single iodixanol
(Optiprep; Sigma Chemical Co., St Louis, MO) gradient or by two
rounds of cesium chloride centrifugation. Pooled fractions were
dialyzed against PBS 35 mM NaCl and concentrated using Amicon
Ultra-15 centrifugal ﬁlter units (Millipore, Billerica, MA), and
frozen after the addition of 5% glycerol.
Neutralizing antibody assays and immunodetection
NAb assay was performed using Huh7 cells as previously
described (Calcedo et al., 2009). The same anti-AAV2 and -AAV8
sera used in the NAb assay were also used to detect puriﬁed intact
vector blotted onto PVDF membranes using a Dot Blot apparatus
(BioRad, Hercules, CA). About 2109 vector genome copies were
diluted to a volume of 200 mL in PBS and applied to a PVDF
membrane. Blots were blocked in 5% nonfat milk in PBS for 1 h at
room temperature, and primary antibody incubations were pre-
formed overnight at 4 1C at the following concentrations: AAV2
serum, 1:2000; AAV8 serum, 1:5000; VP51 serum, 1:5000; A20
monoclonal antibody, 1:200; ADK8 monoclonal antibody, 1:1000;
B1 monoclonal antibody, 1:50. Following washes in PBS 0.05%
Tween20 and 1 h incubation with the appropriate HRP conjugate
antibody, signal was detected using SuperSignal West Pico Che-
miluminescent Substrate (Pierce, Rockford, IL) for 5 min followed
by exposure to X-ray ﬁlm. The VP51 antibody was a kind gift from
Jürgen Kleinschmidt.
Animal procedures
Six to eight-week old male C57BL/6 mice were purchased from
The Jackson Laboratory (Bar Harbor, ME), and housed in the
Animal Facility of the Translational Research Laboratories. All
experimental procedures were in accordance with protocols
approved by the Institutional Animal Care and Use Committee of
the University of Pennsylvania. Recombinant AAV vector was
injected intravenously in 150 mL–350 mL volumes, depending on
the viral titer. All animal injections were performed by the Animal
Models Core at the Gene Therapy Program of the University of
Pennsylvania. For organ lysate studies, mice were euthanized via
CO2 inhalation immediately prior to dissection. Small pieces of
tissue were placed into 2 mL test tubes containing Luciferase Assay
Buffer (Promega, Madison, WI) as well as a 5 mm stainless steel
bead (QIAGEN). Tissues were lysed using a Tissue Lyser (QIAGEN)
and cleared by centrifugation for 5 min at full-speed (4 1C). About
15 mL lysate was loaded onto a clear-bottomed, black-walled 96-
well plate and assayed using a Luminometer after injection of
100 mL of a luciferin solution (Promega) onto each well. Protein
concentration was determined using a MicroBCA assay (Pierce) for
signal normalization.
Isolation of nuclei from fresh mouse liver
Livers were minced in isoosmotic buffer (250 mM sucrose,
25 nM KCl, 5 mM MgCl2, 50 mM Tris [pH 7.5], 0.5% NP40, 1 mM
PMSF) and homogenized in a 15 mL Dounce glass homogenizer
(Wheaton, Millville, NJ) with a loose-ﬁtting pestle. Cells were then
lysed with a tight-ﬁtting pestle, and the suspension was spun for
10 min at 3000 rpm. Pellets were resuspended in 5 mL buffer,
ﬁltered through a 70 mm cell strainer into 40 mL of buffer and spun
for 20 min at 1500 rpm. Pellets were gently resuspended in 3 mL
of buffer and strained once more, followed by the addition of 3 mL
high-sucrose buffer (78% w/v sucrose, 50 mM Tris [pH 7.5], 25 mM
KCl, 5 mMMgCl2) and gentle swirling. This mixture was layered on
top of a 4 mL sucrose buffer cushion in a 14 mL ultraclear
ultracentrifuge tube (Beckman Coulter, Brea, CA), and spun at
10,000 rpm for 30 min. The ﬁnal pellet was resuspended in 400 mL
1  DNAseI incubation buffer (Roche, Switzerland), divided into
100 mL aliquots, ﬂash-frozen and stored at 80 1C. All steps were
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conducted in a cold room on ice and all spins were done at 4 1C or
below. About 2 mL aliquots of each puriﬁcation step were stained
with Trypan blue and visually inspected. Final puriﬁed nuclei were
consistently free of cellular debris at 400 magniﬁcation.
DNAseI treatment of nuclei and qPCR detection of uncoated vs. intact
vector genomes
Nuclei aliquots were incubated overnight with 50 U DNAseI
(Roche) at 37 1C. About 200 mL proteinase K buffer (10 mM Tris [pH
7.5], 10 mM MgCl2, 10 mM EDTA, 0.6% SDS, 2 mg/mL Proteinase K
[QIAGEN]) was added to digested and undigested nuclei aliquots.
After 2 h incubation at 55 1C, DNA was extracted using phenol:
chloroform:isoamyl (Invitrogen) followed by chloroform. DNA was
precipitated from the aqueous layer by adding 1/10 volume
sodium acetate (pH 5.5) and 1 volume of isopropanol, and spun
for 30 min at 5000 rpm at 4 1C, washed with 500 mL 70% ethanol
and spun again for 5 min. Final pellets were air-dried and
resuspended in Tris-EDTA buffer (pH 8.0). In order to quantify
the proportion of uncoated vector genomes in each sample,
genome copy number measured by qPCR in either 10 or 100 ng
DNA from digested nuclear aliquots was subtracted from the
measurements obtained from undigested aliquots.
Heparin binding
For analysis of heparin binding, 51010 GC puriﬁed vectors
were loaded onto equilibrated 1 mL HiTrap Heparin HP columns
(GE Healthcare, UK) at a ﬂow rate of 1 mL/min using an FPLC
system. After sample injection, columns were washed with 10
volumes PBS and eluted with 5 volumes of PBS containing 1 M
NaCl. All ﬂow-through, wash and elution fractions were collected,
pooled, heated at 95 1C for 5 min and ﬁnally applied onto a PVDF
membrane using a Dot Blot apparatus. Blotting with B1 antibody
was performed as described above.
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